An open label study to evaluate the Anti-Acne potential of the Kogigold cream in reduction of inflammatory and non-inflammatory acne lesion on oily & or mixed skin types of volunteers. ?. - NIL

Start Date03 Jun 2024

Sponsor / Collaborator

Sami-Sabinsa Group Ltd.

[+1]

CTRI/2024/02/062721 / CompletedPhase 3

A randomized doubleblind placebocontrolled three arm parallel study to evaluate the safety of FructoSpore in healthy human volunteers

Start Date30 Apr 2024

Sponsor / Collaborator

Sami-Sabinsa Group Ltd.

100 Clinical Results associated with Sami-Sabinsa Group Ltd.

0 Patents (Medical) associated with Sami-Sabinsa Group Ltd.

225

Literatures (Medical) associated with Sami-Sabinsa Group Ltd.

09 Aug 2024·MEDICINE

A randomized, double-blind, placebo-controlled study to evaluate the benefits of a standardized Nigella sativa oil containing 5% thymoquinone in reducing the symptoms of seasonal allergy

Article

Author: Murali, Avinash ; Chandrashekar, Harshith ; Parameswarappa, Avinash Kadasiddappa ; Siddegowda, Chikkalingaiah ; Mundkur, Lakshmi ; Gudimallam, Satish ; Majeed, Anju ; Majeed, Shaheen

Background::

Allergic rhinitis (AR) or seasonal allergy characterized by sneezing, nasal congestion, nasal itching, and nasal discharge, triggered by immune reactions to environmental allergens. Present day customers also monitor the personal improvements in the area of Evidence-Based natural medicines/supplements

Methods::

A randomized, double-blind, placebo-controlled study was conducted on 65 participants aged 18 to 60 years having 2 or more allergic symptoms like sneezing, rhinorrhoea, nasal obstruction, and nasal itching for a cumulative period greater than 1 hour per day. The study participants received a capsule of NSO (250 mg) with 2.5 mg piperine (BioPerine) as a bioavailability enhancer or a placebo, twice a day, after food for 15 days. The primary objectives were evaluated by mean change in Total Nasal Symptom Score and the duration of AR symptoms per day from baseline to Day 15. Secondary endpoints were changes in Total Ocular Symptoms Score, AR symptom frequency and severity, serum Immunoglobulin E levels, and Patient Global Impression of Change scale. Adverse events were monitored throughout the study.

Results::

Sixty-five patients were enrolled and all of them completed the study, N = 33 in NSO and N = 32 in placebo. A significant reduction in Total Nasal Symptom Score and Total Ocular Symptoms Score was observed in the NSO group compared to the placebo, highlighting the potential of NSO in alleviating AR symptoms. The episodes of AR symptoms per day and the frequency of symptoms in 24 hours reduced significantly in 15 days in both groups, but the extent of improvement was significantly higher in NSO compared to placebo. Improvement in Patient Global Impression of Change was also significantly better in NSO compared to the placebo. Serum Immunoglobulin E levels decreased in NSO but were not significantly different from placebo. No clinically significant changes were observed in vital signs, liver and renal function, lipid profile, hematology, fasting blood sugar, or urine analysis at the end of the study.

Conclusion::

The result of the study demonstrates that NSO 250 mg with 2.5 mg piperine is an effective and well-tolerated supplement for the management of AR symptoms.

01 Aug 2024·Current medicinal chemistry

The Combined Effect of Curcumin and Crocin on the Reduction of Inflammatory Responses in Arthritic Rats

Article

Author: Nemati, Houshang ; Rashidi, Khodabakhsh ; Korani, Mitra ; Jamialahmadi, Tannaz ; Sahebkar, Amirhossein ; Abbasifard, Mitra ; Majeed, Muhammed ; Shahraki, Raheleh ; Korani, Shahla

Background::

The present study evaluated the anti-arthritic impact of combined crocin and curcumin on Adjuvant Induced Arthritis (AIA) in rats.

Methods::

The arthritis model was induced in rats by injecting Complete Freund’s adjuvant (CFA) into the right hind paw and was subsequently treated with crocin and curcumin. Evaluation of anti-arthritic activity was carried out using paw swelling, hematological parameters, biochemical parameters, inflammatory cytokines, and histopathology of rats.

Results::

The results showed increased paw swelling, increased serum markers levels, including CRP, RF, ALP, ALT, and AST, and inflammatory cytokines (ILlβ and TNFα) along with histology changes (cartilage and bone degradation) in arthritic rats when compared to the normal group. Crocin, curcumin and crocin + curcumin administration at different doses (especially combination at 40 mg/kg and 30 mg/kg, respectively), as well as MTX, revealed a suitable therapeutic effect on AIA rats. Moreover, both phytochemicals and their combination at different doses showed effective anti-arthritic effects owing to their anti-inflammatory effects

Conclusions::

Crocin and curcumin, either alone or in combination, can be a suitable treatment modality for rheumatoid arthritis.

01 Aug 2024·Clinical Nutrition ESPEN

Evaluation of the effectiveness of curcumin and piperine co-supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation, and clinical outcomes after coronary artery bypass graft surgery

Article

Author: Tehrani, Sahar Dadkhah ; Hosseini, Alireza ; Heidari, Zahra ; Askari, Gholamreza ; Shahzamani, Mehran ; Bagherniya, Mohammad ; Majeed, Muhammed ; Sahebkar, Amirhossein

BACKGROUND:

Coronary artery bypass graft (CABG) is one of the preferred treatments for patients with heart problems, especially in individuals with other comorbidities and when multiple arteries are narrowed. This study aimed to assess the effects of administrating curcumin-piperine on patients who underwent CABG surgery.

METHODS:

This was a randomized, double-blind, placebo-controlled clinical trial, in which 80 eligible adults who underwent CABG surgery, were randomized into 4 groups. Patients received 3 tablets daily for 5 days after the surgery, which contained curcumin-piperine (each tablet contained 500 mg curcumin +5 mg piperine) or a placebo (each tablet contained 505 mg maltodextrin). Group A received 3 placebo tablets, group B received 2 placebos and one curcumin-piperine tablet, group C received 1 placebo and 2 curcumin-piperine tablets, and group D received 3 curcumin-piperine tablets. Before and after the intervention, C-reactive protein (CRP), total antioxidant capacity (TAC), cardiometabolic factors, clinical outcomes, and 28-day mortality were evaluated.

RESULTS:

Between-group analysis showed that CRP significantly decreased (P = 0.028), and TAC significantly increased (P = 0.033) after the intervention (Post hoc analysis showed that for CRP, the difference was between group B and D, and for TAC was between group C and D). Between-group analysis also showed that creatine kinase mono-phosphate (CK-MB) marginally reduced (P = 0.077); however, changes for troponin I (P = 0.692), lactate dehydrogenase (LDH) (P = 0.668), ejection fraction (P = 0.340), and arterial fibrillation (P = 0.99) were not significant. Blood urea nitrogen (P = 0.820) and serum creatinine (P = 0.244) did not show notable changes between groups.

CONCLUSION:

Supplementation with curcumin-piperine had a promising effect on serum CRP and TAC. It also had a favorable impact on CK-MB among patients who underwent CABG surgery.

TRIAL REGISTRATION:

IRCT20201129049534N4, available on https://en.irct.ir/trial/56930.

News (Medical) associated with Sami-Sabinsa Group Ltd.

28 Apr 2018

·www.bioportfolio.com

Global Probiotics Probiotic Products Market Research Report 2018 [Report Updated: 05032018] Prices from USD $3500

Summary Market Segment as follows: By Region AsiaPacific North America Europe South America Middle East Africa By Type Bifidobacterium Lactobacillus Others By Application Food Beverage Drugs Dietary Supplements Others By Company DuPont Danisco Chr. Hansen Lallemand ChinaBiotics Nestle Danone Probi BioGaia Yakult Novozymes Valio Glory Biotech Ganeden Morinaga Milk Industry Sabinsa Greentech Bioriginal Biosearch Life UAS Laboratories Synbiotech The main contents of the report including: Section 1: Product definition, type and application, global and regional market overview; Section 2: Global and regional Market competition by company; Section 3: Global and regional sales revenue, volume and price by type; Section 4: Global and regional sales revenue, volume and price by application; Section 5: Regional export and import; Section 6: Company information, business overview, sales data and product specifications; Section 7: Industry chain and raw materials; Section 8: SWOT and Porter's Five Forces; Section 9: Conclusion.

100 Deals associated with Sami-Sabinsa Group Ltd.

100 Translational Medicine associated with Sami-Sabinsa Group Ltd.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Sami-Sabinsa Group Ltd.

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 23 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing